Epstein Secrets

Series E $117M $1.00 36.2% IRR $6.88 DACART CAPITAL LIC EFTA_R1_01138846 EFTA02295572 Advisory Board Thomas Shenk, Ph.D. Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American

l College of Physicians of Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians. DACART CAPITAL LLC EFTA_R1_01138847 EFTA02295573 Advisory Board Pamela R. Contag, Ph.D. Dr. Contag most recently served as Founder and CEO of Cobalt Technologies, Inc. a venture- backed biofuels company, and rai

E $17M $117M 4) cr 1 .UU nn 36.2% IRR 4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American

balt Biofuels Mar-07 II ,„„-13 Series B Series E $17M $117M 4) cr 1 .UU nn 36.2% IRR 4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipien

r the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American

ly • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipien